Author: Penning, T.D.

Source: Current Pharmaceutical Design, Volume 7, Number 3, 1 February 2001 , pp. 163-179(17)

Publisher: Bentham Science Publishers

Abstract:

Leukotriene A 4 (LTA4 ) hydrolase is a zinc containing enzyme which stereospecifically catalyzes the hydrolysis of the epoxide LTA 4 to the diol leukotriene B 4 (LTB4 ). There is substantial evidence that LTB 4 plays a significant role in the amplification of many inflammatory disease states. Therapeutic agents which selectively inhibit LTA4 hydrolase would block the formation of LTB4 and thus be potentially useful for the treatment of inflammation. Numerous inhibitors of LTA4 hydrolase have been reported over the past 15 20 years. Several early inhibitors were based on the structure of the natural substrate, LTA4 . Later approaches utilized known inhibitors of related zinc containing metalloproteinases and led to the identification of captopril, bestatin and kelatorphan as potent inhibitors of LTA4 hydrolase. This led to the design of a number of peptide and non peptide analogs which contained potential zinc chelating moieties, including thiols, hydroxamates and norstatines. A more recent series of non peptidic, non zinc chelating inhibitors of LTA4 hydrolase has been reported. This work led to the identification of several novel classes of analogs, including imidazopyridines, amidines and cyclic and acyclic amino acid derivatives, ultimately resulting in the identification of two potential clinical candidates SC 56938 and SC 57461A.

Keywords: Leukotrine A4 hydrolase; Anti inflammatory agent; bestatin and kelatrophan; proliferated activated receptor; aminopeptidase activity; zinc binding ligands; epoxy benzoic acid; Angiotensin converting enzyme; Zinc chelating inhibitors; carrageenan induced; phenyl ring

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013398248

Publication date: 2001-02-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Penning, T.D.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers